Targeting T-cell subsets to achieve remission

Journal of the European Academy of Dermatology and Venereology

Volumn 17, Issue SUPPL. 2, 2003, Pages 6-11

  Christophers, E ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Alefacept; CD4+ cells; CD45RA+ T cells; CD45RO+ T cells; CD8+ cells; PASI; PGA; Psoriasis; T cell subsets

Indexed keywords

ALEFACEPT; CD45 ANTIGEN; PLACEBO;

ADULT; AGED; APOPTOSIS; ARTICLE; BRONCHITIS; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EFFECTOR CELL; FEMALE; FLU LIKE SYNDROME; GENETIC ENGINEERING; HERPES SIMPLEX; HUMAN; IMMUNOGENICITY; IMMUNOPATHOGENESIS; INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MULTICENTER STUDY; PHARYNGITIS; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PSORIASIS; RECOMBINANT FUSION PROTEINS; REFERENCE VALUES; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 0037592152     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-3083.17.s2.2.x     Document Type: Article

References (9)

1. Sigmundsdottir H, Gudjonsson JE, Jonsdottir I, Ludviksson BR, Valdimarsson H. The frequency of CLA+CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin Exp Immunol 2001; 126: 365-369.
2. Bos JD, Hagenaars C, Das PK, Krieg SR, Voorn WJ, Kapsenberg ML. Predominance of 'memory' T cells (CD4+, CDw29+) over 'naive' T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res 1989; 281: 24-30.
3. Ferenczi K, Burack L, Pope M, Krueger JG, Austin LM. CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. J Autoimmun 2000; 14: 63-78.
4. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-255.
5. Brottier P, Boumsell L, Gelin C, Bernard A. T cell activation via CD2 [T, gp50] molecules: accessory cells are required to trigger T cell activation via CD2-D66 plus CD2-9.6/T11 (1) epitopes. J Immunol 1985;135:1624-1631.
6. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994; 152: 2753-2767.
7. Miller GT, Hochman PS, Meier W et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993; 178: 211-222.
8. Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996;335:1369-1377.
9. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 135: 1104-1110.